Moving to more novel antidiabetic agents, a metanalysis of six clinical trials with 5250 DM patients showed that dipeptidyl peptidase-4 (DPP-4) inhibitors did not have any significant impact on AF risk, and in fact, increased the risk of atrial flutter [242]. This evidence concerns the gene DPP4 and atrial fibrillation.